Akshay Vaishnaw - Concepedia

Author

Akshay Vaishnaw

Also Known As

A VAISHNAW, A. K. Vaishnaw, A. Vaishnaw, A.K Vaishnaw, A.K. Vaishnaw, Akshay K Vaishnaw, Akshay K. Vaishnaw, Akshay Vaishnaw

Publications

13.6K

Citations

H-Index

Concepts

All Affiliations

Alnylam Pharmaceuticals (United States)University College London The Royal Free Hospital Covance (United Kingdom)University of Tennessee Health Science Center

About

Akshay Vaishnaw is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, pharmacology, and molecular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	1.8K
2	Natural Sciences	4	4	365
3	Biochemistry	3	3	661
4	Allergy	1	1	434
5	Cell Biology	1	1	13

Akshay Vaishnaw

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis David Adams, Alejandra González‐Duarte, William O’Riordan, New England Journal of Medicine	2018	2.8K
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis Teresa Coelho, David Adams, Ana Silva, New England Journal of Medicine	2013	947
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 Kevin Fitzgerald, Suellen White, Anna Borodovsky, New England Journal of Medicine	2016	738
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso, Cancer Discovery	2013	691
A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis Dimitrios T. Boumpas, Richard Furie, Susan Manzi, Arthritis & Rheumatism	2003	609
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya, The Lancet Metabolic SyndromeOxysterolBiochemistryCardiovascular DiseaseHealthy Volunteers	2013	571
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria Manisha Balwani, Eliane Sardh, Paolo Ventura, New England Journal of Medicine	2020	562
<i>Fas</i>Gene Mutations in the Canale–Smith Syndrome, an Inherited Lymphoproliferative Disorder Associated with Autoimmunity Jörn Drappa, Akshay Vaishnaw, Kathleen E. Sullivan, New England Journal of Medicine	1996	481
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1 Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton, New England Journal of Medicine	2021	469
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis Scott D. Solomon, David Adams, Arnt V. Kristen, Circulation	2019	450

Page 1